stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Gross margin
Insmed, Inc.'s gross margin over the twelve months to 30 September 2026 was 84.4%, up 4.7 percentage points from fiscal 2025 (79.7%). Over the past ten years it has ranged from 0.00% (fiscal 2017) to 82.3% (fiscal 2019); the current reading is higher than 90% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 79.7% | 3.30 |
| FY2024 | 76.4% | (2.09) |
| FY2023 | 78.5% | 0.99 |
| FY2022 | 77.5% | 0.96 |
| FY2021 | 76.6% | 0.82 |
| FY2020 | 75.8% | (6.51) |
| FY2019 | 82.3% | 6.90 |
| FY2018 | 75.4% | 75.36 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 85.1% | 0.89 |
| Jun 2026 | 84.2% | (0.30) |
| Mar 2026 | 84.5% | 1.26 |
| Dec 2025 | 83.2% | 3.87 |
| 27 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| EXEL Exelixis, Inc. compare | 96.3% |
| BBIO BridgeBio Pharma, Inc. compare | 94.3% |
| GMAB Genmab A/S Sponsored ADR compare | 93.0% |
| INCY Incyte Corporation compare | 92.7% |
| ASND Ascendis Pharma A/S compare | 91.3% |
| INSM Insmed, Inc. | 84.4% |
| ROIV Roivant Sciences Ltd. compare | 81.2% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 77.3% |
| BNTX BioNTech SE Sponsored ADR compare | 74.6% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement